CDR2 抗原和 Yo 抗体。
CDR2 antigen and Yo antibodies.
机构信息
Department of Neurology, Haukeland University Hospital, Bergen, Norway.
出版信息
Cancer Immunol Immunother. 2011 Feb;60(2):283-9. doi: 10.1007/s00262-010-0943-9. Epub 2010 Nov 16.
Abstract
Paraneoplastic cerebellar degeneration (PCD) is often associated with Yo antibodies that are directed against human cerebellar degeneration-related protein 2 (CDR2). Such antibodies may also be found in ovarian cancer patients without PCD. We studied if there was an association between Yo antibody production and differences in CDR2 cDNA sequence, mRNA or CDR2 expression in ovarian cancers. We found similar CDR2 cDNA sequence, mRNA and protein levels in primary ovarian cancers, with or without associated Yo antibodies. CDR2 was also present in other cancers, as well as in normal ovary tissue. The results suggest that Yo antibodies are not only related to the expression of CDR2 alone, but also to immune dysregulation.
摘要
副肿瘤性小脑变性（PCD）常与针对人类小脑变性相关蛋白 2（CDR2）的 Yo 抗体有关。此类抗体也可能存在于无 PCD 的卵巢癌患者中。我们研究了 Yo 抗体产生与卵巢癌中 CDR2 cDNA 序列、mRNA 或 CDR2 表达差异之间是否存在关联。我们发现，无论是否伴有 Yo 抗体，原发性卵巢癌中 CDR2 的 cDNA 序列、mRNA 和蛋白水平相似。CDR2 也存在于其他癌症以及正常卵巢组织中。结果表明，Yo 抗体不仅与 CDR2 的表达有关，还与免疫失调有关。
相似文献
1
CDR2 antigen and Yo antibodies.
Cancer Immunol Immunother. 2011 Feb;60(2):283-9. doi: 10.1007/s00262-010-0943-9. Epub 2010 Nov 16.
2
Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies.
Cancer Immunol Immunother. 2017 Nov;66(11):1463-1471. doi: 10.1007/s00262-017-2041-8. Epub 2017 Jul 14.
3
CDR2L Antibodies: A New Player in Paraneoplastic Cerebellar Degeneration.
PLoS One. 2013 Jun 18;8(6):e66002. doi: 10.1371/journal.pone.0066002. Print 2013.
4
Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration.
Acta Neuropathol. 2018 Apr;135(4):569-579. doi: 10.1007/s00401-017-1802-y. Epub 2018 Jan 3.
5
Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo--associated paraneoplastic cerebellar degeneration.
Neuro Oncol. 2012 Apr;14(4):506-10. doi: 10.1093/neuonc/nos006. Epub 2012 Feb 20.
6
Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies.
Br J Cancer. 2018 Jul;119(1):105-113. doi: 10.1038/s41416-018-0125-7. Epub 2018 Jun 14.
7
A cerebellar degeneration-related protein 2-like cell-based assay for anti-Yo detection in patients with paraneoplastic cerebellar degeneration.
Eur J Neurol. 2023 Jun;30(6):1727-1733. doi: 10.1111/ene.15786. Epub 2023 Mar 26.
8
Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique.
Clin Exp Immunol. 2006 Apr;144(1):53-8. doi: 10.1111/j.1365-2249.2006.03031.x.
9
Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity.
Neuropathol Appl Neurobiol. 2019 Feb;45(2):141-156. doi: 10.1111/nan.12492. Epub 2018 May 24.
10
CDR2L Is the Major Yo Antibody Target in Paraneoplastic Cerebellar Degeneration.
Ann Neurol. 2019 Aug;86(2):316-321. doi: 10.1002/ana.25511. Epub 2019 Jun 13.
引用本文的文献
1
Autoimmune Encephalitis With Autoimmune Diabetes: A Case of Horror Autotoxicus.
Cureus. 2023 Jan 27;15(1):e34268. doi: 10.7759/cureus.34268. eCollection 2023 Jan.
2
Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration.
Neurol Neuroimmunol Neuroinflamm. 2022 Jul 12;9(5). doi: 10.1212/NXI.0000000000200015. Print 2022 Sep.
3
Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic Marker.
Neurol Neuroimmunol Neuroinflamm. 2021 Feb 2;8(2). doi: 10.1212/NXI.0000000000000963. Print 2021 Mar.
4
MicroRNA 452 regulates ASB8, NOL8, and CDR2 expression in colorectal cancer cells.
Genes Genomics. 2021 Jan;43(1):33-41. doi: 10.1007/s13258-020-01016-5. Epub 2021 Jan 4.
5
Localization of CDR2L and CDR2 in paraneoplastic cerebellar degeneration.
Ann Clin Transl Neurol. 2020 Nov;7(11):2231-2242. doi: 10.1002/acn3.51212. Epub 2020 Oct 3.
6
Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications.
Front Immunol. 2020 Jun 2;11:991. doi: 10.3389/fimmu.2020.00991. eCollection 2020.
7
Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes.
Neurol Neuroimmunol Neuroinflamm. 2020 Mar 13;7(3). doi: 10.1212/NXI.0000000000000701. Print 2020 May.
8
Paraneoplastic cerebellar degeneration with bilateral facial palsy: a rare primary presentation of breast cancer.
BMJ Case Rep. 2018 Jun 21;2018:bcr-2018-224996. doi: 10.1136/bcr-2018-224996.
9
Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity.
Neuropathol Appl Neurobiol. 2019 Feb;45(2):141-156. doi: 10.1111/nan.12492. Epub 2018 May 24.
10
Utility of paraneoplastic antigens as biomarkers for surveillance and prediction of recurrence in ovarian cancer.
Cancer Biomark. 2017 Dec 6;20(4):369-387. doi: 10.3233/CBM-170652.
本文引用的文献
1
HLA-DQ2+ individuals are susceptible to Hu-Ab associated paraneoplastic neurological syndromes.
J Neuroimmunol. 2010 Sep 14;226(1-2):147-9. doi: 10.1016/j.jneuroim.2010.05.035. Epub 2010 Jun 12.
2
The onconeural antigen cdr2 is a novel APC/C target that acts in mitosis to regulate c-myc target genes in mammalian tumor cells.
PLoS One. 2010 Apr 7;5(4):e10045. doi: 10.1371/journal.pone.0010045.
3
Antibody to CCDC104 is associated with a paraneoplastic antibody to CDR2 (anti-Yo).
Cancer Immunol Immunother. 2010 Feb;59(2):231-7. doi: 10.1007/s00262-009-0742-3.
4
Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response.
Oncogene. 2009 Sep 17;28(37):3274-85. doi: 10.1038/onc.2009.186. Epub 2009 Jul 6.
5
Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies.
Acta Neurol Scand. 2009 Jul;120(1):64-7. doi: 10.1111/j.1600-0404.2008.01138.x.
6
Molecular analysis of the HuD gene in neuroendocrine lung cancers.
Lung Cancer. 2010 Jan;67(1):69-75. doi: 10.1016/j.lungcan.2009.03.022.
7
Onconeural antibodies in sera from patients with various types of tumours.
Cancer Immunol Immunother. 2009 Nov;58(11):1795-800. doi: 10.1007/s00262-009-0690-y. Epub 2009 Mar 18.
8
Regulatory T cells in paraneoplastic neurological syndromes.
J Neuroimmunol. 2008 May 30;196(1-2):166-9. doi: 10.1016/j.jneuroim.2008.03.002. Epub 2008 May 1.
9
Paraneoplastic neurological syndromes and onconeural antibodies: clinical and immunological aspects.
Adv Clin Chem. 2007;44:143-85. doi: 10.1016/s0065-2423(07)44005-7.
10
Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique.
Clin Exp Immunol. 2006 Apr;144(1):53-8. doi: 10.1111/j.1365-2249.2006.03031.x.
Zotero 插件